NCT07815496

Brief Summary

This study aims to investigate the modulation of intranasally administered oxytocin (24 IU) on human fairness perception and related prosocial behaviors.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
3mo left

Started Sep 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress25%
Sep 2026Dec 2026

First Submitted

Initial submission to the registry

September 3, 2026

Completed
2 days until next milestone

Study Start

First participant enrolled

September 5, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 11, 2026

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

September 11, 2026

Status Verified

September 1, 2026

Enrollment Period

4 months

First QC Date

September 3, 2026

Last Update Submit

September 8, 2026

Conditions

Keywords

oxytocinfMRIfairness perceptionprosocial behavior

Outcome Measures

Primary Outcomes (4)

  • Fairness rating scores

    Participants are asked to rate their perceived levels of fairness on a 9-point Likert scale (1 = highly fair, 9 = highly unfair) to the computer's allocation in each trial.

    1 hour

  • Anticipated guilt rating scores

    Participants are asked to rate the anticipated guilt they would feel if they accepted the allocation given by the computer in each trial. Ratings were conducted on a 9-point Likert scale (1 = not at all, 9 = highly guilty).

    1 hour

  • The binary decision to the initial allocation

    Participants are asked to makde decisions of accepting or rejecting the allocation provided by the computer in each trial.

    1 hour

  • Brain activity patterns

    Brain activity patterns in response to the outcome of the allocation given by computer and the binary decision. We will examine these brain response patterns via both the conventional univariate analysis and the machine learning-based multivariate pattern analysis (MVPA) approaches.

    1 hour

Secondary Outcomes (1)

  • Inequity aversion parameters derived from the Fehr-Schmidt model

    1 hour

Study Arms (2)

oxytocin group

EXPERIMENTAL

male and female subjects with oxytocin treatment

Drug: Oxytocin nasal spray

placebo group

PLACEBO COMPARATOR

male and female subjects with placebo treatment

Drug: Placebo

Interventions

intranasal administration of oxytocin (24IU)

oxytocin group

intranasal administration of placebo (24IU)

placebo group

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy subjects without past or current psychiatric or neurological disorders.

You may not qualify if:

  • History of head injury; pregnant, menstruating, taking oral contraceptives; medical or psychiatric illness.
  • The presence of metal in the body or claustrophobia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, 611731, China

RECRUITING

MeSH Terms

Conditions

Altruism

Condition Hierarchy (Ancestors)

Social BehaviorBehavior

Study Officials

  • Shuxia Yao, Dr

    University of Electronic Science and Technology of China

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

September 3, 2026

First Posted

September 11, 2026

Study Start

September 5, 2026

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

September 11, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations